Prevention of rupture of atherosclerotic plaque by Candesartan in rabbit model.
- Author:
Xin-fu ZHOU
1
;
Hong-chao YIN
;
Wen-ling ZHU
;
Li SHEN
;
Tao YU
;
Shang-ai LI
;
Zi-min MENG
;
Ai-shan WU
;
Huan-de QIAN
Author Information
- Publication Type:Journal Article
- MeSH: Angiotensin II Type 1 Receptor Blockers; therapeutic use; Animals; Antihypertensive Agents; therapeutic use; Aorta, Abdominal; injuries; Benzimidazoles; therapeutic use; Collagen; metabolism; Macrophages; pathology; Male; Matrix Metalloproteinase 9; metabolism; Plaque, Atherosclerotic; metabolism; pathology; Rabbits; Random Allocation; Rupture, Spontaneous; prevention & control; Tetrazoles; therapeutic use; Thrombosis; etiology; metabolism; prevention & control
- From: Chinese Journal of Pathology 2010;39(2):106-111
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo evaluate Candesartan therapeutic effect against atherosclerotic plaque rupture and to explore the related mechanisms.
METHODSThirty-four New Zealand White male rabbits were randomly divided into three groups: the control group, the model control group and the Candesartan intervention group. The control group rabbits were fed with a normal diet. Rabbits of the latter two groups were fed with a 1% high-cholesterol diet and received a balloon catheter injury respectively one week after the cholesterol feeding. Candesartan (0.5 mgⁱkg⁻¹ⁱd⁻¹) was given to the Candesartan group rabbits 2 days before the performance of the balloon catheter injury. By the end of 12(th) week of the experiment, Russell's viper venom was used for rabbits of both the model control and the Candesartan groups in order to induce rupture of the plaques developed and followed by sacrifice of all the rabbits of the 3 groups. The aortas were removed and fixed for histological evaluation. Immunohistochemistry of MMP-9, macrophage markers and collagen were performed. The protein expression of MMP-9 was determined using Western blot analysis.
RESULTSIn the model control group, 7 of 9 rabbits with a total of 12 plaques developed rupture and thrombosis of the plaques after the induction. In contrast, only 2 of 10 rabbits with a total of 3 plaques demonstrated rupture and thrombosis in the Candesartan group (P < 0.05). The control group rabbits did not have plaque rupture and thrombosis. Compared with the model group, both the percentage area of MMP-9 and macrophages in the plaques were significantly decreased in the Candesartan group (12.35% ± 4.28% vs 32.58% ± 9.16%, P < 0.05; 13.87% ± 4.91% vs 23.8% ± 7.45%, P < 0.05). There was an increased percentage of collagen content in total plaques of the Candesartan group (30.27% ± 11.36% vs 4.18% ± 1.28%, P < 0.01). Compared with the model group, the protein expression of MMP-9 was significantly decreased in the Candesartan group (P < 0.01).
CONCLUSIONCandesartan has a preventive value against atherosclerotic plaque rupture in hypercholesterolemic rabbits, likely through its reduction of MMP-9 expression, inhibition of macrophage accumulation and increase of collagen content within the plaques.